Advanced search
1 file | 473.80 KB
Author
Organization
Abstract
Cystinosis is a rare, autosomal recessive inherited lysosomal storage disease. It is the most frequent and potentially treatable cause of the inherited renal Fanconi syndrome. If left untreated, renal function rapidly deteriorates towards end-stage renal disease by the end of the first decade of life. Due to its rarity and nonspecific presentation, the entity is often not promptly recognized resulting in delayed diagnosis. Two major milestones in cystinosis management, cystine-depleting therapy with cysteamine and renal allograft transplantation, have had a considerable impact on the natural history and prognosis of cystinosis patients. However, due to its significant side effects and a strict 6-hourly dosing regimen, non-adherence to the immediate release of cysteamine bitartrate formulation (Cystagon((R))) is a major issue that might affect long-term outcome. Recently, a new twice-daily administered delayed-release enteric-coated formula of cysteamine bitartrate (Procysbi((TM))) has been approved by the European Medical Agency for the treatment of cystinosis, and has been shown to be safe and effective. This delayed-release cysteamine has the potential to improve compliance and hence prognosis, through its better dosing regimen, positive impact on quality of life and possibly less side-effects, and is now tested in an ongoing long-term clinical trial. Longer survival of patients with cystinosis makes transition from pediatric to adult-oriented care another challenge in cystinosis management and requires an extended multidisciplinary approach.
Keywords
Management, Cystinosis, Cysteamine, Delayed-release, Transition to adult care, RELEASE CYSTEAMINE BITARTRATE, NEPHROPATHIC CYSTINOSIS, FANCONI-SYNDROME, FOLLOW-UP, THERAPY, CHILDREN, DYSFUNCTION, DIAGNOSIS, HALITOSIS, PATTERN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 473.80 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Veys, Koenraad RP, MARTINE BESOUW, Anne-Marie Pinxten, Maria Van Dyck, Ingele Casteels, and Elena N Levtchenko. 2016. “Cystinosis : a New Perspective.” Acta Clinica Belgica 71 (3): 131–137.
APA
Veys, K. R., BESOUW, M., Pinxten, A.-M., Van Dyck, M., Casteels, I., & Levtchenko, E. N. (2016). Cystinosis : a new perspective. ACTA CLINICA BELGICA, 71(3), 131–137.
Vancouver
1.
Veys KR, BESOUW M, Pinxten A-M, Van Dyck M, Casteels I, Levtchenko EN. Cystinosis : a new perspective. ACTA CLINICA BELGICA. 2016;71(3):131–7.
MLA
Veys, Koenraad RP et al. “Cystinosis : a New Perspective.” ACTA CLINICA BELGICA 71.3 (2016): 131–137. Print.
@article{5864438,
  abstract     = {Cystinosis is a rare, autosomal recessive inherited lysosomal storage disease. It is the most frequent and potentially treatable cause of the inherited renal Fanconi syndrome. If left untreated, renal function rapidly deteriorates towards end-stage renal disease by the end of the first decade of life. Due to its rarity and nonspecific presentation, the entity is often not promptly recognized resulting in delayed diagnosis. Two major milestones in cystinosis management, cystine-depleting therapy with cysteamine and renal allograft transplantation, have had a considerable impact on the natural history and prognosis of cystinosis patients. However, due to its significant side effects and a strict 6-hourly dosing regimen, non-adherence to the immediate release of cysteamine bitartrate formulation (Cystagon((R))) is a major issue that might affect long-term outcome. Recently, a new twice-daily administered delayed-release enteric-coated formula of cysteamine bitartrate (Procysbi((TM))) has been approved by the European Medical Agency for the treatment of cystinosis, and has been shown to be safe and effective. This delayed-release cysteamine has the potential to improve compliance and hence prognosis, through its better dosing regimen, positive impact on quality of life and possibly less side-effects, and is now tested in an ongoing long-term clinical trial. Longer survival of patients with cystinosis makes transition from pediatric to adult-oriented care another challenge in cystinosis management and requires an extended multidisciplinary approach.},
  author       = {Veys, Koenraad RP and BESOUW, MARTINE and Pinxten, Anne-Marie and Van Dyck, Maria and Casteels, Ingele and Levtchenko, Elena N},
  issn         = {1784-3286},
  journal      = {ACTA CLINICA BELGICA},
  keywords     = {Management,Cystinosis,Cysteamine,Delayed-release,Transition to adult care,RELEASE CYSTEAMINE BITARTRATE,NEPHROPATHIC CYSTINOSIS,FANCONI-SYNDROME,FOLLOW-UP,THERAPY,CHILDREN,DYSFUNCTION,DIAGNOSIS,HALITOSIS,PATTERN},
  language     = {eng},
  number       = {3},
  pages        = {131--137},
  title        = {Cystinosis : a new perspective},
  url          = {http://dx.doi.org/10.1179/2295333714Y.0000000113},
  volume       = {71},
  year         = {2016},
}

Altmetric
View in Altmetric
Web of Science
Times cited: